ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
"Cancer research relevant to LMICs is a necessity, not a luxury," writes Dr. Khalid El Bairi, and early-career oncologists in LMIC settings can advance cancer research in their communities.
"If you are young researcher in an LMIC trying to launch your own career, I highly recommend building collaborations and networks with oncologists around the globe," said Dr. Khalid El Bairi.
Dr. Leslie M. Randall, Dr. Mark Stoler, and I explore the decline in cervical cancer incidence which has not corresponded to a decline in deaths from high-risk invasive disease.
If luck, as Louis Pasteur noted, favors the prepared mind, how will oncologists not only prepare but extend cognitive capacity in an era where both medical knowledge and the scope of human endeavor that physicians must address continue to increase exponentially?
Despite limitations, some winds of change are noticeable regarding clinical research in the Latin America and Caribbean region, according to Dr. Matías Chacón, Dr. Diego Enrico, and Dr. Federico Waisberg.
"It is my hope that 10 years from now we will look back on this time—one in which the pandemic laid bare glaring inequities in health care—as an inflection point," said Michael Burton.
"2020 will be a year we at CancerLinQ look back on with mixed emotion because, in the midst of the pandemic, we achieved a momentous milestone," said Dr. Danielle Potter.
Peer review, writes Dr. Yara Abdou, is not a task, but a privilege, and an invaluable experience for the reviewer to enhance their critical thinking and engage in an invigorating academic community.
A spirit of clinically relevant discovery and accessible, understandable knowledge dissemination is the profound legacy, responsibility, and obligation that Rich will leave at ASCO, and we will honor him by continuing this work at the level of rigor and quality he established.
By holding its scientific program on time, ASCO and the entire oncology community make a pledge that we will continue advancing and offering the best care for our patients worldwide.
The number of new and old agents being suggested as COVID-19 therapies seems to be expanding exponentially. Dr. Donald L. Trump, Dr. Courtney W. Houchen, and Dr. Milton L. Brown highlight current investigations.
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Pages
Advertisement